



~~Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.~~

Subpart 1C/SBPA (00-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Do not submit a collection of information unless it contains a valid OMB control number.

(continued)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/645,655
		Filing Date	August 20, 2003
		First Named Inventor	Joseph W. St. Germe III
		Group Art Unit	Not yet assigned → 1645
		Examiner Name	Not yet assigned → CRAIS
Sheet	1	of	3
		Attorney Docket Number	

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	7/6/09
--------------------	---	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

*** Applicant is to place a check mark here if English Language Translation is attached.**

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 113328_1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO (Modified)				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/645,655
Sheet	2	of	3	Filing Date	August 20, 2003
				First Named Inventor	Joseph W. St. Germe III
				Group Art Unit	Not yet assigned <i>1645</i>
				Examiner Name	Not yet assigned <i>Grace</i>
				Attorney Docket Number	A-59941-3/RFT/THR

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
<i>J</i>	C1	BAKALETZ, L.O., et al., "Frequency of Fimbriation of nontypable <i>Haemophilus influenzae</i> and Its Ability To Adhere to Chinchilla and Human Respiratory Epithelium", <i>Infection and Immunity</i> , 1988, 56(2): 331-335.
	C2	BARENKAMP, S.J., et al., "Cloning Expression, and DNA Sequence Analysis of Genes Encoding Nontypeable <i>Haemophilus influenzae</i> High-Molecular-Weight Surface-Exposed Proteins Related to Filamentous Hemagglutinin of <i>Bordetella pertussis</i> ", <i>Infection and Immunity</i> , 1992, 60(4):1302-1313.
	C3	BENZ, I., et al., "AIDA-I, the adhesin involved in diffuse adherence of the diarrhoeagenic <i>Escherichia coli</i> strain 2787 (O126:H27), is synthesized via a precursor molecule", <i>Molecular Microbiology</i> , 1992, 6(11):1539-1546.
	C4	BRENNAN, M.J., et al., "Identification of a 69-Kilodalton Nonfimbrial Protein As an Agglutinogen of <i>Bordetella pertussis</i> ", <i>Infection and Immunity</i> , 1988, 56(12):3189-3195.
	C5	CHARLES, I.G., et al., "Molecular cloning and characterization of protective outer membrane protein p. 69 from <i>Bordetella pertussis</i> ", <i>Proc. Natl. Acad. Sci. USA</i> , 1989, pp. 86:3554-3558.
	C6	EWANOWICH, C.A., et al., "Invasion of HeLa 229 Cells by Virulent <i>Bordetella pertussis</i> ", <i>Infection and Immunity</i> , 1989, 57(9):2698-2704.
	C7	FORSGREN, J., et al., "Haemophilus influenzae Resides and Multiplies Intracellularly in Human Adenoid Tissue as Demonstrated by In Situ Hybridization and Bacterial Viability Assay", <i>Infection and Immunity</i> , 62(2):673-679, (1994).
	C8	GULIG et al., "Immunogenic Proteins in Cell-Free Culture Supernatants of <i>Haemophilus influenzae</i> Type b," <i>Infection & Immunity</i> 44:41-48, 1984.
	C9	ISBERG, R.R., et al. "Identification of Invasin: A Protein That Allows Enteric Bacteria to Penetrate Cultured Mammalian Cells", <i>Cell</i> , 60:769-778, (1987).
	C10	KOOMEY, J.M., et al., "Nucleotide Sequence Homology Between the Immunoglobulin A1 Protease Genes of <i>Neisseria gonorrhoeae</i> , <i>Neisseria meningitidis</i> , and <i>Haemophilus influenzae</i> ", <i>Infection and Immunity</i> , 1984, 43(1):101-107.
	C11	KRIVAN, H.C., et al., "Many pulmonary pathogenic bacteria bind specifically to the carbohydrate sequence Ga1NAc beta-1-4Gal found in some glycolipids", <i>Proc. Natl. Acad. Sci. USA</i> , 1988, 85:6157-6161.
	C12	LEININGER, E., et al., "Pertactin, an Arg-Gly-Asp-containing <i>Bordetella pertussis</i> surface protein that promotes adherence of mammalian cells", <i>Proc. Natl. Acad. Sci. USA</i> , 1991, 88:345-349.
	C13	LEININGER, E., et al., "Comparative Roles of the Arg-Gly-Asp Sequence Present in the <i>Bordetella pertussis</i> Adhesins Pertactin and Filamentous Hemagglutinin", <i>Infection and Immunity</i> , 1992, 60(6):2380-2385.
	C14	PICHICHERO, M.E., "Do Pili Play A Role In Pathogenicity of <i>Haemophilus influenzae</i> Type B", <i>The Lancet</i> , 1982, 56(2) 960-962.
	C15	POHLNER, J., et al., "Gene Structure and extracellular secretion of <i>Neisseria gonorrhoeae</i> IgA protease", <i>Nature</i> , 1987, 325(29):458-462.
	C16	POULSEN, K., et al., "Cloning and Sequencing of the Immunoglobulin A1 Protease Gene (iga) of <i>Haemophilus influenzae</i> Serotype b", <i>Infection and Immunity</i> , 1989, 57(10):3097-3105.
	C17	POULSEN, K., et al., "A Comparative Genetic Study of Serologically Distinct <i>Haemophilus influenzae</i> Type I Immunoglobulin A1 Proteases", <i>Journal of Bacteriology</i> , 1992, 174(9):2913-2921.
<i>J</i>	C18	PROVENCE, D.L., et al., "Isolation and Characterization of a Gene Involved in Hemagglutination by an Avian Pathogenic <i>Escherichia coli</i> Strain", <i>Infection and Immunity</i> , 1994, 62(4):1369-1380.

Examiner Signature	<i>Grace</i>	Date Considered	<i>7/6/04</i>
--------------------	--------------	-----------------	---------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 1133328_1

Under the Paperwork Reduction Act of 1985, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO (Modified)		<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/645,655
		Filing Date	August 20, 2003
		First Named Inventor	Joseph W. St. Geme III
		Group Art Unit	Not yet assigned <i>1645</i>
		Examiner Name	Not yet assigned <i>Graser</i>
Sheet	3	of	3
		Attorney Docket Number	
		A-59941-3/RFT/THR	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Signature *[Signature]* **Date Considered** *7/6/04*

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

*** Applicant is to place a check mark here if English Language Translation is attached.**

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 113328_1



PATENT
Attorney Docket No. A-59941-3/RFT/THR
Dorsey File No. 467084-66

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

ST. GEME, III et al.

U.S. Serial No.: 10/645,655

Filing Date: August 20, 2003

For: *HAEMOPHILUS ADHERENCE
AND PENETRATION PROTEINS*

Examiner: To Be Assigned

Art Unit: To Be Assigned

CERTIFICATE OF MAILING

I hereby certify that this correspondence, including listed enclosures, is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. BOX 1450, Alexandria, VA 22313-1450 on March 3, 2004.

Signed: Joyce Abriam
Joyce Abriam

**INFORMATION DISCLOSURE STATEMENT AND
STATEMENT OF RELATEDNESS**

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

In satisfaction of the duty of disclosure under 37 C.F.R. § 1.56, and in accordance with the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants wish to draw the attention of the U.S. Patent and Trademark Office to the references cited on the accompanying form PTO/SB/8A-B. Since copies of the references were provided either by the Applicant or the Examiner in the following related U.S. Applications: Serial No. 09/839,996, filed April 20, 2001 (now U.S. Patent No. 6,642,371), and Serial No. 08/296,791, filed August 25, 1994 (now U.S. Patent No. 6,245,337), upon which the instant application relies for its priority date, in accordance with 37 C.F.R. § 1.98(d), no copies of these references are enclosed.

U.S. Serial No.: 10/645,655
Filing Date: August 20, 2003

None of the foregoing references is believed to disclose the invention as claimed.

Nothing herein shall constitute an admission concerning the contents of any of the cited references, nor shall the inclusion of a reference herein be considered an admission that the reference constitutes prior art against the invention claimed in the above-identified application. Submission of the present document shall not be construed as an admission that a search has been made or that better art does not exist.

As far as is known to the undersigned, this Information Disclosure Statement is being filed within three months of the filing date of a national application, within three months of the date of entry of the national state in an international application, or before the mailing date of a first Office Action on the merits as set forth in 37 C.F.R. § 1.97(b), and therefore no fee is required.


While no fee is believed to be due, if this belief is in error the Commissioner is authorized to charge any additional fees, including extension fees or other relief which may be required, or credit any overpayment to Deposit Account No. 50-2319 (Our Order No. 467084-66 [A-59941-3/RFT/THR]).

Please direct any calls in connection with this application to the undersigned at (415) 544-7024.

Respectfully submitted,
DORSEY & WHITNEY LLP

Dated: March 3, 2004
Dorsey & Whitney LLP
Intellectual Property Department
Four Embarcadero Center, Suite 3400
San Francisco, CA 94111-4187
Telephone: (415) 544-7024
Facsimile: (415) 398-3249

BY:


Traci H. Ropp, Reg. No. 44,307 for
Richard F. Trecartin, Reg. No. 31,801
Filed under 37 C.F.R. §1.34(a)
Customer Number: 32940